Clinical trials: Precancerous Conditions
Leukemia, Leukemia, Myeloid
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Study BH-30236-01 is a first-in-human (FIH), Phase 1/1b, open-label, dose escalation and expansion study in participants with relapsed/refractory acute myelogenous leukemia (R/R AML) or higher-risk myelodysplastic syndrome…
- Conditions
- Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Preleukemia
- Trial name
- NCT06501196
- Testing
- BH-30236, Venetoclax
- Where
- 13 sites in United States
- Volunteers
- 170 people
- Sponsor
- BlossomHill Therapeutics
Actinic Keratosis
Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2)
This clinical trial serves the purpose to compare the long-term effects of a treatment of actinic keratosis - your skin disorder - using Aldara® 5% cream (Imiquimod) or Solaraze® 3% gel (Diclofenac) on the face or the scalp.
- Trial name
- LEIDA 2 (NCT01453179)
- Testing
- Imiquimod, Diclofenac
- Where
- 17 sites in Austria, Germany
- Volunteers
- 221 people
- Sponsor
- MEDA Pharma GmbH & Co. KG
Cervical Intraepithelial Neoplasia
Study of SOR007 Ointment for Cervical Intraepithelial Neoplasia (CIN)
This is a Phase 2, open-label, dose-rising study evaluating the safety, tolerability, and preliminary efficacy of three concentrations of SOR007 ointment (0.15%, 1.0%, and 2.0%) applied topically once per week for four weeks to…
- Trial name
- NCT03143491
- Testing
- SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment
- Sponsor
- DFB Soria, LLC
Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion
REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
HPV-301 is a prospective, randomized, double-blind, placebo controlled Phase 3 study to determine the efficacy, safety, and tolerability of VGX-3100 administered by intramuscular (IM) injection followed by electroporation (EP)…
- Conditions
- Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
- Trial name
- REVEAL 1 (NCT03185013)
- Testing
- VGX-3100, Electroporation (EP)
- Where
- 60 sites in United States, Argentina and 17 more
- Volunteers
- 201 people
- Sponsor
- Inovio Pharmaceuticals
Actinic Keratosis
Evaluation of Two Different Non-invasive Techniques to Monitor the Clearance of Actinic Keratosis Lesions
The purpose of this study is to evaluate the performance of two techniques to monitor the clearance of AK lesions when treated with Aldara 5% cream.
- Trial name
- NCT00294320
- Testing
- Aldara (Imiquimod), Vehicle cream
- Where
- France
- Volunteers
- 12 people
- Sponsor
- MEDA Pharma GmbH & Co. KG
Keratosis
Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands
The purpose of this study is to evaluate the safety and efficacy of imiquimod 5% cream compared to vehicle cream in the treatment of Actinic Keratosis (AK) on the arm and/or hand when the cream is applied once daily 2 days per…
- Trial name
- NCT00115154
- Testing
- Aldara (imiquimod) cream, 5%
- Where
- 18 sites in United States
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Graceway Pharmaceuticals, LLC
Actinic Keratosis
Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis
This study is to evaluate the efficacy and safety of a generic formulation of fluorouracil 0.5% cream against the brand product (Carac) in participants with actinic keratoses.
- Trial name
- NCT02616601
- Testing
- Generic Fluorouracil Cream, Carac® (Fluorouracil) Cream, Vehicle Cream
- Where
- 17 sites in United States
- Volunteers
- 422 people, healthy volunteers welcome
- Sponsor
- Actavis Inc.
Actinic Keratosis
Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp
The purpose of this study is to compare the efficacy of Photodynamic Therapy (PDT) with methyl aminolevulinate (MAL) cream to PDT with vehicle cream, using the the LED light source Aktilite CL128, in treatment of patients with…
- Trial name
- NCT00306800
- Testing
- Photodynamic therapy with methyl aminolevulinate cream
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- Galderma R&D
Actinic Keratosis
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Actinic Keratoses
The purpose of this study is to determine whether topical application of PEP005 is safe for the treatment of actinic keratoses.
- Trial name
- NCT00107965
- Testing
- PEP005
- Where
- 6 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Peplin
Actinic Keratoses
Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face
A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Assess the Efficacy and Safety of Methyl aminolevulinate hydrochloride (MAL) 16.8% cream (CD06809-41) versus vehicle cream in the treatment of thin and…
- Trial name
- NCT04085367
- Testing
- MAL 16.8% cream, MAL Vehicle Cream
- Where
- 60 sites in United States, Puerto Rico
- Volunteers
- 557 people
- Sponsor
- Galderma R&D
Actinic Keratosis
A Long Term Follow up Study of Patients Who Have Complete Clearance of Their Actinic Keratosis (AK) Lesions at the Day 57 Visit in the PEP005-028 Study
This study is designed to follow up patients, who have participated in the PEP005-028 study and observed complete clearance of their Actinic Keratosis (AK) lesions, over a 12 month period to assess both recurrence of AK lesions…
- Trial name
- NCT00989313
- Testing
- Lesion count
- Where
- 17 sites in United States
- Volunteers
- 43 people
- Sponsor
- Peplin
Actinic Keratosis
Eight Week Study of Treatment With DFD-07 for Actinic Keratosis of the Face and Scalp
The purpose of this study is to see how well DFD-07 works in treating actinic keratosis on the face and scalp during 8 weeks of treatment. The study will also look at any unwanted effects of the study drug.
- Trial name
- NCT02654717
- Testing
- DFD-07 Cream
- Where
- 3 sites in Germany
- Volunteers
- 111 people
- Sponsor
- Promius Pharma, LLC
Actinic Keratosis (AK)
Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%
The purpose of the study is to compare the risk of developing squamous skin cancer (SCC) or other types of cancer after treatment of AKs with ingenol mebutate gel or imiquimod cream.
- Trial name
- NCT01926496
- Testing
- Ingenol Mebutate Gel, 0.015%, Imiquimod Cream, 5%
- Where
- 46 sites in France, Germany and 1 more
- Volunteers
- 485 people
- Sponsor
- LEO Pharma
Actinic Keratoses
Therapeutic Equivalence of Fluorouracil Cream, 5% Compared With Fluorouracil 5% Topical Cream of MylanPharmaceuticals Inc., U.S.A in the Treatment of Actinic Keratosis
Fluorouracil is recommended for the topical treatment of multiple actinic or solar keratoses. In the 5% strength, it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical…
- Trial name
- NCT05078827
- Testing
- Test Product (A): Fluorouracil Cream, 5% topical cream, Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A.
- Where
- 7 sites in United States
- Volunteers
- 458 people
- Sponsor
- Encube Ethicals Pvt. Ltd.
Actinic Keratosis
Study on the Safety and Efficacy of Bimiralisib Gel in Participants Suffering From Actinic Keratosis
The aim of the study is to evaluate efficacy and safety of bimiralisib gel treatment for treatment of actinic keratosis (AK) on the face and/or scalp and/or back of hands
- Trial name
- NCT06319794
- Testing
- Bimiralisib
- Where
- 2 sites in Switzerland
- Volunteers
- 46 people
- Sponsor
- TORQUR
Precancerous Conditions, Carcinoma
Early Diagnosis of Pulmonary Nodules
This study is intended to determine the positive predictive value (PPV) and negative predictive value (NPV) of the multiprotein classifier based on the observed study prevalence of Non-Small Cell Lung Cancer (NSCLC) in the study…
- Trial name
- NCT01752114
- Where
- 33 sites in United States, Canada
- Volunteers
- 684 people, healthy volunteers welcome
- Sponsor
- Integrated Diagnostics
Actinic Keratosis
Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp
The purpose of the study is to demonstrate that ingenol mebutate gel is efficacious in treating Actinic Keratoses (AKs) present 8 weeks after initial field treatment or emerging in a previously cleared field.
- Trial name
- NCT01600014
- Testing
- Ingenol mebutate gel, 0.015%, Vehicle gel
- Where
- 13 sites in Australia, Canada and 3 more
- Volunteers
- 463 people
- Sponsor
- LEO Pharma
Uterine Cervical Neoplasms, Cervix Intraepithelial Neoplasia
Safety and Tolerability of Cidofovir Gel Applied on Cervix Squamous Lesions
Human Papilloma Virus (HPV) infections induce cervical intraepithelial neoplasia (CIN) of cervix. To reduce incidence of invasive tumor associated with high grade CIN lesions, the standard treatment is the conisation of cervix…
- Trial name
- NCT00989443
- Testing
- Cidofovir gel
- Where
- Belgium
- Volunteers
- 6 people
- Sponsor
- Mithra Pharmaceuticals
Actinic Keratosis
A Multi-Center Study to Evaluate the Efficacy and Safety of KX01 Ointment 1% on Actinic Keratosis on Face or Scalp
This Phase III study is designed to evaluate the efficacy and safety of KX01 Ointment in adult participants when applied to an area of skin containing more than 1, clinically typical Actinic Keratosis (AK) lesions on the face or…
- Trial name
- NCT05231044
- Testing
- KX01 ointment 1%
- Where
- 20 sites in Japan
- Volunteers
- 108 people
- Sponsor
- PharmaEssentia
Actinic Keratosis
Dose-finding, Safety, Efficacy Trial of Topical Resiquimod in Patients With Multiple Actinic Keratosis Lesions
A Dose-Finding Study of Resiquimod Evaluating Safety and Efficacy in Patients with Multiple Actinic Keratosis Lesions
- Trial name
- NCT01583816
- Testing
- Resiquimod 0.03%, Resiquimod 0.01%
- Where
- 10 sites in Germany, Switzerland
- Volunteers
- 218 people
- Sponsor
- Spirig Pharma Ltd.